Pretarsal application of botulinum toxin for treatment of blepharospasm

Aramideh, M; Ongerboer de Visser, B W; Brans, J W; Koelman, J H; Speelman, J D
September 1995
Journal of Neurology, Neurosurgery & Psychiatry;Sep1995, Vol. 59 Issue 3, p309
Academic Journal
journal article
No abstract available.


Related Articles

  • Primary Blepharospasm: Diagnosis and Management. Defazio, Giovanni; Livrea, Paolo // Drugs;2004, Vol. 64 Issue 3, p237 

    Primary blepharospasm is an adult-onset focal dystonia characterised by involuntary contractions of the orbicularis oculi muscles. Patients may have various types of movements arising from the different parts of the orbicularis oculi muscle. These include typical blepharospasm associated with...

  • Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. Ã‡akmur, Raif; Ozturk, Vesile; Uzunel, Fatma; Donmez, Beril; Idiman, Fethi // Journal of Neurology;Jan2002, Vol. 249 Issue 1, p64 

    Although the beneficial effect of subcutaneous injections of botulinum toxin type A (BTX-A) is well known in both blepharospasm and hemifacial spasm, the position of the injection sites around the orbicularis oculi may influence the effectiveness and side effects. Here we report results of...

  • Botox applications continue to expand. Jesitus, John // Dermatology Times;May2004, Vol. 25 Issue 5, p94 

    Reports on the wide acceptance for botulinum toxin treatments in the U.S. Administration for botulinum toxins; Procedures for botulinum toxin treatments; Efficacy of botulinum toxin applications.

  • Effect of treatment with botulinum toxin on neurogenic blepharospasm. Elston, J.S.; Russell, R.W. Ross // British Medical Journal (Clinical Research Edition);6/22/1985, Vol. 290 Issue 6485, p1857 

    Examines the effects of botulinum toxin for the treatment of neurogenic blepharospasm. Development of flaccid paralysis following injection into the skeletal muscle; Occurrence of local side effects; Mechanism of botulinum toxin.

  • Complete secondary botulinum toxin therapy failure in blepharospasm. Dressler, Dirk // Journal of Neurology;Oct2000, Vol. 247 Issue 10, p809 

    Presents a letter to the editor about secondary botulinum toxin therapy failure in blepharospasm.

  • VIEWS.  // BMJ: British Medical Journal (International Edition);9/1/90, Vol. 301 Issue 6749, p450 

    Focuses on issues related to medicine. Occurrence of eosinophilia myalgia syndrome; Efficacy of botulinum toxin as treatment of blepharospasm torticollis; Discussion on the ideal weight during pregnancy.

  • Bilateral upper eyelid ectropion associated with blepharospasm. Kob, S.; Hosohato, J.; Tano, Y. // British Journal of Ophthalmology;Nov2006, Vol. 90 Issue 11, p1437 

    A letter to the editor is presented regarding an unusual case of bilateral upper eyelid ectropion associated with blepharospasm in an elderly man who responded to treatment with botulinum A toxin.

  • Botox: 'Wonder drug of this century' Hrehocik, Maureen // Dermatology Times;Sep2004, Vol. 25 Issue 9, p94 

    Presents a study investigating the safety of botulinum toxin type A. Data about the safety of the cosmetic use of botulinum toxin type A; Clearance given by the U.S. Food and Drug Administration to botulinum toxin type A for the treatment of blepharospasm and strabismus; Demonstration of the...

  • Therapeutic uses of botulinum toxin. Jankovic, J.; Brin, M.F. // New England Journal of Medicine;4/25/91, Vol. 324 Issue 17, p1186 

    Reviews the rationale for the use of botulinum toxin in the treatment of a variety of neurologic and ophthalmologic disorders. Mechanism of action of botulinum toxin; Clinical applications of botulinum toxin.

  • Botulinum Toxin in Medical Therapy. Skorin Jr., Leonid // Review of Optometry;7/15/2004, Vol. 141 Issue 7, p53 

    Focuses on the use of botulinum toxin in medical therapy in the U.S. Treatment of blepharospasm, strabismus, and other ocular muscle disorders; Inhibition of the release of acetylcholine from the nerve terminal; Availability of two immunologically distinct neurotoxins for clinical use in the...


Read the Article


Sign out of this library

Other Topics